Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo

Citations Over TimeTop 10% of 2013 papers

Related Papers

• → Successful Treatment of Non-small Cell Lung Cancer with Gefitinib after Severe Erlotinib-related Hepatotoxicity(2012)26 cited
• Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.(2010)
• Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.(2014)
• Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer(2009)
• Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment(2011)